232 related articles for article (PubMed ID: 8547650)
1. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
3. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
5. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
[TBL] [Abstract][Full Text] [Related]
6. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
8. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Gandhi V; Estey E; Keating MJ; Plunkett W
Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
12. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
13. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
14. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
15. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Gandhi V; Du M; Kantarjian HM; Plunkett W
Leukemia; 1994 Sep; 8(9):1463-8. PubMed ID: 8090026
[TBL] [Abstract][Full Text] [Related]
16. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Gandhi V; Nowak B; Keating MJ; Plunkett W
Blood; 1989 Nov; 74(6):2070-5. PubMed ID: 2478221
[TBL] [Abstract][Full Text] [Related]
17. On the interaction between cytosine arabinoside and etoposide in vivo and in vitro.
Liliemark J; Knochenhauer E; Gruber A; Pettersson B; Björkholm M; Peterson C
Eur J Haematol; 1993 Jan; 50(1):22-5. PubMed ID: 8436210
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.
Albertioni F; Lindemalm S; Reichelova V; Pettersson B; Eriksson S; Juliusson G; Liliemark J
Clin Cancer Res; 1998 Mar; 4(3):653-8. PubMed ID: 9533533
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
[TBL] [Abstract][Full Text] [Related]
20. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
